NV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
Yuto Hasegawa, Xiaolei Zhu, and Atsushi Kamiya
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Atsushi Kamiya, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Meyer 3-146, Baltimore, Maryland 21287, USA. Phone: 410.502.0060; Email: akamiya1@jhmi.edu.
Find articles by Hasegawa, Y. in: JCI | PubMed | Google Scholar
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Atsushi Kamiya, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Meyer 3-146, Baltimore, Maryland 21287, USA. Phone: 410.502.0060; Email: akamiya1@jhmi.edu.
Find articles by
Zhu, X.
in:
JCI
|
PubMed
|
Google Scholar
|
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Atsushi Kamiya, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Meyer 3-146, Baltimore, Maryland 21287, USA. Phone: 410.502.0060; Email: akamiya1@jhmi.edu.
Find articles by
Kamiya, A.
in:
JCI
|
PubMed
|
Google Scholar
|
First published May 20, 2019 - More info
J Clin Invest. 2019;129(6):2207–2209. https://doi.org/10.1172/JCI129702.
© 2019 American Society for Clinical Investigation
Growing evidence implicates altered mTORC1 signaling cascades in the pathophysiology of depression, suggesting that direct modulation of mTORC1 signaling may offer novel therapeutic potential. In this issue of the JCI, Kato and colleagues reported that administration of NV-5138, a recently developed synthetic leucine analog, has a rapid and sustained antidepressant action in rat models via activation of mTORC1 signaling. The investigators also found that the antidepressant effect of NV-5138 is mediated by upregulation of brain-derived neurotrophic factor (BDNF) signaling and that NV-5138 treatment produces rapid synaptic responses in the medial prefrontal cortex. These findings highlight the direct activation of mTORC1 signaling as a potential pharmacological intervention for the treatment of depression.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)